These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 4678834)

  • 1. Urinary metabolites from rats given L-DOPA.
    Borud O; Midtvedt T; Gjessing LR
    Acta Pharmacol Toxicol (Copenh); 1972; 31(5):540-9. PubMed ID: 4678834
    [No Abstract]   [Full Text] [Related]  

  • 2. Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat.
    Goldin BR; Peppercorn MA; Goldman P
    J Pharmacol Exp Ther; 1973 Jul; 186(1):160-6. PubMed ID: 4723308
    [No Abstract]   [Full Text] [Related]  

  • 3. Excretion of dopa metabolites.
    Kott E; Bornstein B; Eichhorn F
    N Engl J Med; 1971 Feb; 284(7):395. PubMed ID: 5539935
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluorometric method for quantitatively estimating urinary dihydroxyphenylethylamine (dopamine), dihydroxyphenylalanine (dopa), and dihydroxyphenylacetic acid (dopac).
    Eichhorn F; Rutenberg A; Kott E
    Clin Chem; 1971 Apr; 17(4):296-300. PubMed ID: 5552365
    [No Abstract]   [Full Text] [Related]  

  • 5. Polyamide thin-layer chromatographic separation of DOPA metabolites and related compounds.
    Harrison SD; Chiu P; Maickel RP
    J Chromatogr; 1973 Oct; 85(1):151-3. PubMed ID: 4754395
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of a screening test for L-dopa and its metabolites in urine.
    Routh JI; Bannow RE
    Clin Chem; 1971 Sep; 17(9):872-4. PubMed ID: 5571486
    [No Abstract]   [Full Text] [Related]  

  • 8. [Qualitative analysis of the main urinary metabolites of dopamine, epinephrine and norepinephrine by gas chromatography].
    Bègue RJ; Bazerolle O; Desgres J; Lallemant C; Padieu P
    Pathol Biol (Paris); 1971; 19(15):719-25. PubMed ID: 4942503
    [No Abstract]   [Full Text] [Related]  

  • 9. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
    Routh JI; Bannow RE; Fincham RW; Stoll JL
    Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
    [No Abstract]   [Full Text] [Related]  

  • 10. Demethylation of L-3-methoxytyrosine in vivo.
    Bartholini G; Pletscher A
    Naunyn Schmiedebergs Arch Pharmacol; 1972; 274(4):404-9. PubMed ID: 4263632
    [No Abstract]   [Full Text] [Related]  

  • 11. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 12. Beta-hydroxylation of N-acetyl-3,4-dimethoxyphenethylamine and the influence of iproniazid on the demethylation of this compound in vivo in the rat.
    Van Winkle E; Schweitzer JW; Friedhoff AJ
    Biochem Pharmacol; 1970 Jun; 19(6):2137-44. PubMed ID: 5513979
    [No Abstract]   [Full Text] [Related]  

  • 13. 2,3,5-Trihydroxyphenylacetic acid. A metabolite of L-3,4-dihydroxyphenylalanine.
    Wada GH; Fellman JH
    Biochemistry; 1973 Dec; 12(25):5212-7. PubMed ID: 4799943
    [No Abstract]   [Full Text] [Related]  

  • 14. Urinary excreion of DOPA and metabolites by patients with melanoma.
    Voorhess ML
    Cancer; 1970 Jul; 26(1):146-9. PubMed ID: 5424526
    [No Abstract]   [Full Text] [Related]  

  • 15. Biochemical investigations in patients with Parkinson's disease treated with L-dopa.
    Jequier E; Dufresne JJ
    Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836
    [No Abstract]   [Full Text] [Related]  

  • 16. Phenolic metabolites in urine and faeces from rats given radioactive 14C-L-DOPA.
    Borud O; Midtvedt T; Gjessing LR
    Acta Pharmacol Toxicol (Copenh); 1973; 33(4):308-16. PubMed ID: 4800677
    [No Abstract]   [Full Text] [Related]  

  • 17. The metabolic pathways of L-3-O-methyldopa.
    Bartholini G; Kuruma I; Pletscher A
    J Pharmacol Exp Ther; 1972 Oct; 183(1):65-72. PubMed ID: 5080035
    [No Abstract]   [Full Text] [Related]  

  • 18. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 19. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa.
    Bianchine JR; Messiha FS; Hsu TH
    Clin Pharmacol Ther; 1972; 13(4):584-94. PubMed ID: 5042372
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.